Neoparin Forte (Enoxaparin Sodium)

Enoxaparin Sodium, the active ingredient in Neoparin Forte, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous or haemodialysis use. It is employed to prevent and treat thromboembolic disorders in adult patients at risk of clot formation.

GNH USA supplies Neoparin Forte as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Enoxaparin Sodium is a low molecular weight heparin used in the prevention and treatment of venous thromboembolism.

- Deep vein thrombosis prophylaxis: reduces the incidence of clot formation in surgical or immobilized patients. - Pulmonary embolism treatment: facilitates clot resolution and prevents recurrence in diagnosed cases. - Anticoagulation during hemodialysis: maintains circuit patency by inhibiting clot formation in the extracorporeal circuit.

Enoxaparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Bruising or hematoma: localized bleeding under the skin. - Minor bleeding: such as nosebleeds or gum bleeding. - Nausea: transient gastrointestinal upset. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening internal bleeding. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop. - Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures. - Severe allergic reaction: anaphylaxis or angioedema.

When using Enoxaparin Sodium, clinicians should observe several safety considerations to minimize risk.

- Bleeding risk: assess for active bleeding or recent surgery before administration. - Renal impairment: adjust dose or monitor closely in patients with reduced kidney function. - Concomitant anticoagulants: avoid or carefully manage use with other blood thinners. - Spinal/epidural procedures: postpone needle placement for at least 12 hours after the last dose. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin Sodium can interact with other medicines, altering its anticoagulant effect.

Major Interactions (Avoid): - Concurrent use with warfarin, direct thrombin inhibitors, or other LMWHs: markedly increases bleeding risk. - Antiplatelet agents (aspirin, clopidogrel, ticagrelor): additive antithrombotic effect may cause severe hemorrhage. - Fibrinolytic therapy (tPA, streptokinase): synergistic effect on clot dissolution heightens bleeding potential.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance minor bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: increase risk of gastrointestinal bleeding. - Certain antibiotics (e.g., vancomycin, linezolid): may affect platelet function and require monitoring.